Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi all,
Does anyone know by when AUPH is supposed to release the details associated with the settlement with SUN. I thought I read in an earlier disclosure that they requested for a 60 day period. That is now over right?
Hi everyone, saw a post in stocktwits that AUPH received 3 million from Sun for the settlement. Is this true?
Wish we can get to know the settlement details soon and hopefully it adds more value. Some thing like a settlement amount plus on going royalty etc.
Termination of the trial also granted. However final written order still pending.
https://ptacts.uspto.gov/ptacts/public-informations/petitions/1549200/download-documents?artifactId=170366469
Aha, thank you. Worst case scenario, I guess we might have to wait for a few more days/weeks then.
Is there a requirement that deal can only happen once we hear from the trail judge? Or is it irrelevant at this point?
Does anyone know how long it typically takes for PATB to respond to appeals? AUPH filed the appeal on August 9th as the per the link below. Checking online, I see conflicting information with regards to response time lasting from 2 months to 15 months.
https://s3-us-west-1.amazonaws.com/ptab-filings%2FIPR2022-00617%2F12
On September 19, 2022, Timothy P. Walbert, a member of the board of directors (the Board) of Aurinia, notified the Company of his intent to resign from the Board, effective at the close of business on September 19, 2022. Mr. Walbert's departure from the Board is not due to any disagreement with the Company or the Board on any matter relating to the operations, policies or practices of the Company.
Above is from the recent 8-k
Jess etc all, does the departure of the director have any impact for or against the assumption of merger talks in the background? Have any you seen this in past mergers?
thx, Longbear
This PR was expected since 9/15. Its delay is what caused many (including me) to hope for the merger news at last. I really hope that news is in the making and will be out soon. Until then however given how crazy market is we might see dips... Fingers crossed, holding strong since after ARIA.
The article just says EU marketing authorization decision will be issued in approximately 2 months. EU already did that on 9/15. BMS also received on 9/15 marketing authorization for Opdualag similar to AUPH and they issued their PR last week itself.
Not sure why AUPH or Otsuka is not issuing a PR when other companies are doing so unless there is something going on in the background that prevents them from doing so.
On the 15th when the alert came up w.r.t marketing authorization, there was no document available. It was noted that it will be available in 48 hrs. Now it is available for downloading. Although it seems not everyone is given access.
That being said, BMY also had a similar EC marketing authorization for which they issued a PR the other day.
My confusion is: if the news for EC is already a public knowledge, shouldn’t that force the company to issue a PR even if there is merger discussions happening?
The link I shared earlier indicates EMA gave approval today.
COMMISSION IMPLEMENTING DECISION granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Lupkynis - voclosporin", a medicinal product for human use
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)6734&lang=en
Unless i am reading this incorrectly.
approved by EMA?
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)6734&lang=en
Not seeing any PR though...
Hi everyone,
Was stuck with work and couldn't get on the call. What was the outcome of AGM? Not able find much info online!
Thank you LB
I wish could that, but I am fully out of cash at this point. Hence my disappointment. I could have had 50% more shares if I had waited. Oh well, as they say hindsight is 20/20
Wow this was not how expected this week to end. Now I wish I waited before I averaged up buying shares in 30s.
I am not good at this “max pain” stuff. But I did sell all my Bcrx holdings and brought more Auph at 32 at the start of November. My average is still below teens so I am not worried. One way or other other I know I will be making a significant amount of money in this stock.
PS: sold Bcrx not because I don’t like that ticker but because in the short term, I am hoping that Auph Will give a more returns. I do intent to get back to Bcrx after this chapter closes.
I am holding till I have details on the deal just like how I did it in ARIA. I hope we go way higher. Fingers crossed. And at this point, thank you to all you great researchers who pointed to AUPH after ARIA.
I really hope that is not the case ( years for BCRX to prove out). Check out the posts on BCRX and decide for yourself. I believe that they will spike at the latest by mid of next year if they don’t get brought out before that.
I hope to see BCRX north of $100/- post the completion of their lasted new studies for which they are enrolling patients 2H of 2021. The preliminary results are expected around mid of next year. Their management is pretty solid. Check out BCRX board they have some good DD there.
Congratulations everyone. Followed the gang from Ariad. So excited
Mine too, Auph is the biggest holding, then BCRX, then TRIL and finally some GBTC. Thinking of opening a position in ITRM.
Thank you Lidopete. Yes it is the purchase by Denver that clued me into. In the mean time holding long on AUPH of course.
Ohayo everyone. Quick question, I found out the Sarissa recently opened a significant position for in ITRM. I was wondering if someone here has a position or opinion about the stock
Thank you that does put my mind at ease.
Gali study to be completed by 05/31/2021?
Hi all,
I recently started a position in BCRX. The following link: https://clinicaltrials.gov/ct2/show/study/NCT03891420 says the estimated primary completion date for Gali study is May 31, 2021.
I thought that the results would out sooner? What am I missing. Obviously a noob, so do pardon my ignorance.
Longbear
Around the time when 13-G came out, Scottrade increased the additional margin requirement to 45% resulting in maintenance calls that needs to be met. This forces me to sell at least some of my holdings in the next two days. Wondering if these two events are related and if it, is it a common practice? Also I wonder how many would be in the same boat like me forced to sell in the onset of a probable good news.
10.9.1 and 10.9.2 pertains to negotiations (?) between ARIAN and Bellicum w.r.t payment agreement and ARIAD trying to renegotiate(?) based on the claim that “ARIAD has certain rights pursuant to its [***] with [***], including a non-exclusive license to certain intellectual property and a separate right to enter negotiations to obtain an exclusive license to intellectual property”.
The CT is with regards to exhibits 10.8, 10.9.1 & 10.9.2 of 10-k filed on March 2, 2015.
10.8 pertains to collaboration agreement between ARIAD and Otsuka w.r.t (but may or may not be limited to):
1) Tablet cost. 2) Patents (granted/pending) in Japan, China, South Korea. 3) Details regarding full royatly Term,
4) Net Sales and determination of payments by Outsuka or it sublicenses. 5) possible new countries/territories for expanding sale. 6) Termination of promotion of Sprycel in Japan by Outsuka. 7) establishing a Joint Development & Commercialization Committee. 8) milestone payments by Outsuka to Aria etc